New drug trial aims to breach Cancer's defenses

NCT ID NCT05753722

Summary

This early-stage study is testing a new drug called PRTH-101, both alone and combined with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it can shrink tumors. Researchers hope PRTH-101 will break down a barrier around tumors, allowing the immune system to attack the cancer cells.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Honor Health Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact

    Contact

  • Mass General Cancer Center

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

    Contact

  • NEXT Houston

    RECRUITING

    Houston, Texas, 77054, United States

    Contact

    Contact

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact

  • Next Oncology

    RECRUITING

    Irving, Texas, 75039, United States

    Contact

    Contact

  • Next Oncology

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact

  • Providence Cancer Institute Franz Clinic

    RECRUITING

    Portland, Oregon, 97213, United States

    Contact

    Contact

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact

  • University of Pittsburgh Medical Center Hillman Cancer Center

    COMPLETED

    Pittsburgh, Pennsylvania, 15232, United States

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 27232, United States

    Contact

    Contact

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06511, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.